会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 신규 D-글루탐산 합성효소 유전자 DNA 및 이를 이용한 항생제 비의존성 벡터
    • 用于恒定高表达的抗生素独立载体和使用该基因表达的基因表达方法
    • KR1020020061022A
    • 2002-07-22
    • KR1020010001690
    • 2001-01-12
    • 주식회사 바이오리더스한국생명공학연구원
    • 성문희이승구홍승표윤은자최윤호부하령이상철
    • C12N15/65
    • C12N15/65
    • PURPOSE: Provided are an antibiotics-independent vector for constant high-expression and a method for gene expression using the same. The antibiotics-independent vector can be applied to high expression of useful DNAs and proteins, and production of recombinant proteins. CONSTITUTION: The antibiotics-independent plasmid vector is constructed by using a major amino acid composing a cell wall and a gene associated with D-glutamic acid synthase, as an auxotrophic maker, and it contains DNA or its fragment which is represented by the SEQ ID NO:1. The antibiotics-independent plasmid vector expresses a foreign gene in the absence of antibiotics, and shows D-glutamic acid synthesis activity in a bacterium. The foreign gene is characteristically selected from the group consisting of nucleic acids coding proteins, anti-sense RNA, and ribozyme. A transformant including the expression vector is cultured without adding antibiotics to its culture medium in order to give proteins.
    • 目的:提供用于恒定高表达的抗生素非依赖载体和使用其的基因表达方法。 抗生素无关载体可用于高表达有用的DNA和蛋白质,以及重组蛋白的产生。 构成:通过使用构成细胞壁的主要氨基酸和与D-谷氨酸合酶相关的基因作为营养缺陷型制剂,构建与抗生素无关的质粒载体,并且其含有由SEQ ID NO:1。 不含抗生素的质粒载体在不存在抗生素的情况下表达外源基因,并在细菌中显示D-谷氨酸合成活性。 外源基因特征性地选自编码蛋白质,反义RNA和核酶的核酸组。 培养包含表达载体的转化体,而不向其培养基中加入抗生素以产生蛋白质。
    • 2. 发明授权
    • 신규 알카리성 리파제, 이를 생산하는 신규 바실러스 균주 및 리파제 대량생산 방법
    • 신규알카리성리파제,이를생산하산신규바실러스균주및리파제대량생산방
    • KR100463350B1
    • 2004-12-29
    • KR1020010061667
    • 2001-10-06
    • 한국생명공학연구원주식회사 바이오리더스
    • 성문희오태광김형권최윤호김광석김영선김철중송재준김광배진우신광순부하령이상철
    • C12N9/14
    • PURPOSE: Provided are a novel alkaline lipase, a novel bacillus sp. strain producing the same, and a method of producing the lipase massively. The non-toxicity bacillus sp. strain is capable of being used in food industry, and the lipase is used for quantitative determination of lipid content. CONSTITUTION: The novel alkaline lipase shows thermostability at 40 deg.C and has an optimum temperature of activity at 35 deg.C. Further, it has no changes with calcium concentrations, and has an optimum activity at pH 8.5. Its amino acid sequence is represented by the SEQ ID NO:1. The novel bacillus sp. strain, bacillus pumilus B26 strain(KTCC 10081BP) produces the lipase. The lipase is mass-produced by transforming bacillus subtilis DB104 with a recombinant vector pMB26 then culturing the transformant. The transformant strain is bacillus subtilis DB104/pMB26(KCTC 10082BP).
    • 目的:提供了一种新型碱性脂肪酶,一种新型的芽孢杆菌。 产生它的菌株,以及大量生产脂肪酶的方法。 无毒芽孢杆菌 菌株能够在食品工业中使用,并且脂肪酶用于定量测定脂质含量。 构成:新型碱性脂肪酶在40摄氏度显示热稳定性,在35摄氏度时具有最佳活性温度。 此外,钙浓度没有变化,并且在pH 8.5时具有最佳活性。 其氨基酸序列由SEQ ID NO:1表示。 新型芽孢杆菌 菌株,短小芽孢杆菌B26菌株(KTCC10081BP)产生脂肪酶。 通过用重组载体pMB26转化枯草芽孢杆菌DB104然后培养转化体来大量生产脂肪酶。 转化株是枯草芽孢杆菌DB104 / pMB26(KCTC10082BP)。
    • 5. 发明授权
    • 미분화 인간 전분화능줄기세포 검출용 조성물, 단일클론항체 6-1 및 이의 용도
    • 用于检测未分化人类预分化干细胞的组合物,单克隆抗体6-1及其用途
    • KR101785909B1
    • 2017-10-17
    • KR1020150099600
    • 2015-07-14
    • 한국생명공학연구원
    • 민정기박종진배광희이상철조이숙
    • G01N33/53C12Q1/68C12N15/115
    • C12Q1/6881C07K16/28C12Q2600/158G01N33/56966G01N2333/705G01N2400/00
    • 본발명은데스모글레인 2(Desmoglein 2, Dsg 2) 유전자의 mRNA 또는이의단백질수준을측정하는제제를포함하는, 미분화된인간전분화능줄기세포검출용조성물, 상기조성물을포함하는미분화된인간전분화능줄기세포검출용키트, 데스모글레인 2 유전자의 mRNA 또는이의단백질수준을측정하는단계를포함하는미분화된인간전분화능줄기세포를검출하는방법, 인간전분화능줄기세포의분화여부를확인하는방법및 미분화된인간전분화능줄기세포를분리하는방법, 데스모글레인 2의발현또는활성을감소시켜인간전분화능줄기세포의미분화상태를감소시키는방법, 인간데스모글레인 2에특이적으로결합하는단일클론항체에관한것이다.
    • 本发明DES雪上技巧泳道2(桥粒芯蛋白2,DSG 2),将含有该试剂测定基因的mRNA或蛋白水平未分化人多能前干细胞检测组合物,未分化的人类前者包含该组合物 多能干细胞的多能干细胞之前检测未分化的人,包括mRNA或测量蛋白水平在试剂盒中的方法,死亡雪上技巧泳道2基因的检测,如何确定是否分化多能干细胞的前人 和减少分离多能干细胞,雪上技巧泳道2的DES表达或活性的未分化人前一种方法,结合该方法的单克隆抗体,所述人死亡雪上技巧泳道2 eteuk转移,以减少围绕多潜能干细胞的人的存在的未分化状态 Lt。
    • 9. 发明公开
    • 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법
    • 筛选蛋白质治疗剂的方法
    • KR1020120107741A
    • 2012-10-04
    • KR1020110025446
    • 2011-03-22
    • 한국생명공학연구원한국과학기술원
    • 이승구김학성김유정이상철한지은이상준김수진손정훈하재석
    • C12Q1/02C12N15/63G01N33/15G01N33/53
    • C07K14/195C07K14/46C07K14/461C07K14/705C07K2319/35C07K2319/70C12N15/70C12Q1/6897G01N33/5023G06F19/16
    • PURPOSE: An assay system for screening a therapeutic agent is provided to maintain structural stability and to analyze the efficacy of a protein therapeutic agent. CONSTITUTION: A method for analyzing the efficacy of a protein therapeutic agent for treating sepsis comprises: a step of transducing a vector with an expression cassette containing a NF-kappaB which binds a motif-conjugated promoter and a gene encoding a reporter protein, and a vector with an expression cassette containing NF-kappaB which binds a motif-free promoter and a gene encoding the reporter protein into a cell line on which an LPS signal transduction receptor is expressed; a step of mixing purified MD-2(myeloid differentiation protein-2), LPS and protein therapeutic agent for treating sepsis; a step of contacting the mixture with the cell line; and a step of determining whether a contacted experimental group has a higher efficacy than a control group when expression level of the reporter protein is less than the control group. [Reference numerals] (AA) Luciola cruciata luciferase; (BB) Renilla luciferase; (CC) LAR II reagent; (DD) Stop&Glow reagent; (EE) Firefly/Renilla = TLR4/MD-2 activation index; (FF) TMB substrate; (GG) Cytokine TNF-alpha, IL-6, etc.
    • 目的:提供用于筛选治疗剂的测定系统以维持结构稳定性并分析蛋白质治疗剂的功效。 构成:用于分析蛋白质治疗剂用于治疗败血症的功效的方法包括:用含有结合基序缀合的启动子的NF-κB和编码报道蛋白的基因的表达盒转导载体的步骤,以及 载体,其含有含有免疫启动子和编码报告蛋白的基因的NF-κB的表达盒进入表达LPS信号转导受体的细胞系中; 混合纯化的MD-2(髓样分化蛋白-2),LPS和治疗败血症的蛋白质治疗剂的步骤; 使混合物与细胞系接触的步骤; 以及当报道蛋白的表达水平低于对照组时,确定接触的实验组是否具有比对照组更高的功效的步骤。 (参考号)(AA)Luciola cruciata萤光素酶; (BB)海肾萤光素酶; (CC)LAR II试剂; (DD)停止&发光试剂; (EE)萤火虫/ Renilla = TLR4 / MD-2激活指数; (FF)TMB底物; (GG)细胞因子TNF-α,IL-6等
    • 10. 发明公开
    • 신규한 MD-2 결합 폴리펩타이드 및 이의 용도
    • 新型MD-2结合多肽及其用途
    • KR1020120022453A
    • 2012-03-12
    • KR1020100086055
    • 2010-09-02
    • 한국과학기술원한국생명공학연구원
    • 김학성이상철한지은이중재김동섭홍승표박근완이승구하재석김유정
    • C07K19/00C12N15/62C12N15/63A61P31/00
    • PURPOSE: A novel polypeptide which specifically binds to MD-2 protein is provided to design a therapeutic agent protein for treating sepsis using VLR scaffolding protein. CONSTITUTION: A polypeptide which specifically binds to MD-2(myeloid differentiation protein-2) protein fused N-terminal of internalin B protein, VLR(vriable lymphocyte receptor)-modified repetitive module, and C-terminal of VLR protein. The polypeptide is sequence number 2, 3, 4, or 5. A repetitive module with high stability through consensus design is a repetitive module of sequence formula 1(LTNLxxLxLxxNQLQSLPxGVFDK). A method for preparing the polypeptide comprises: a step of preparing a vector containing a nucleic acid encoding the polypeptide; a step of introducing the vector to host cells; and a step of collecting polypeptides from the host cells.
    • 目的:提供特异性结合MD-2蛋白的新型多肽,以设计使用VLR脚手架蛋白治疗败血症的治疗剂蛋白质。 构成:特异性结合MD-2(骨髓分化蛋白-2)蛋白的多肽融合内蛋白B蛋白的N末端,VLR(可变淋巴细胞受体)修饰的重复模块和VLR蛋白的C末端。 多肽是序列号2,3,4或5.通过共有设计具有高稳定性的重复模块是序列式1(LTNLxxLxLxxNQLQSLPXGVFDK)的重复模块。 制备该多肽的方法包括:制备含有编码该多肽的核酸的载体的步骤; 将载体引入宿主细胞的步骤; 以及从宿主细胞收集多肽的步骤。